|
AR090151A1
(es)
*
|
2012-03-07 |
2014-10-22 |
Lilly Co Eli |
Compuestos inhibidores de raf
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
TWI704151B
(zh)
|
2014-12-22 |
2020-09-11 |
美商美國禮來大藥廠 |
Ｅｒｋ抑制劑
|
|
BR112018075371A2
(pt)
*
|
2016-06-10 |
2019-03-19 |
Novartis Ag |
usos terapêuticos de um inibidor de c-raf
|
|
EP3558979B1
(en)
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
WO2018200981A1
(en)
*
|
2017-04-28 |
2018-11-01 |
Quartz Therapeutics, Inc. |
Raf-degrading conjugate compounds
|
|
PL3728254T3
(pl)
|
2017-12-21 |
2023-06-12 |
Boehringer Ingelheim International Gmbh |
Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
|
|
JP7161849B2
(ja)
*
|
2018-01-24 |
2022-10-27 |
株式会社クラレ |
第一級アミンの製造方法
|
|
CN118903436A
(zh)
|
2018-01-31 |
2024-11-08 |
德西费拉制药有限责任公司 |
治疗肥大细胞增多症的组合疗法
|
|
KR102708177B1
(ko)
|
2018-01-31 |
2024-09-23 |
데시페라 파마슈티칼스, 엘엘씨. |
위장관 기질 종양의 치료를 위한 병용 요법
|
|
US12208099B2
(en)
|
2018-09-10 |
2025-01-28 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
SMT202500389T1
(it)
|
2018-12-28 |
2025-11-10 |
Deciphera Pharmaceuticals Llc |
Inibitori di csf1r per l'uso nel trattamento di tumori tenosinoviali a cellule giganti
|
|
JP7451543B2
(ja)
|
2019-02-06 |
2024-03-18 |
イーライ リリー アンド カンパニー |
Ｋｃｎｑ増強剤としての１－（（２－（２，２，２－トリフルオロエトキシ）ピリジン－４－イル）メチル）尿素誘導体
|
|
TWI756636B
(zh)
*
|
2019-02-18 |
2022-03-01 |
美商建南德克公司 |
嘧啶并嘧啶化合物及使用方法
|
|
IL330104A
(en)
|
2019-03-11 |
2026-08-01 |
Deciphera Pharmaceuticals Llc |
Crystalline forms of rifatinib
|
|
CN114072148A
(zh)
*
|
2019-05-03 |
2022-02-18 |
金耐特生物制药公司 |
Raf激酶的抑制剂
|
|
HRP20231310T1
(hr)
|
2019-05-10 |
2024-02-02 |
Deciphera Pharmaceuticals, Llc |
Heteroarilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
|
|
HUE065486T2
(hu)
|
2019-05-10 |
2024-05-28 |
Deciphera Pharmaceuticals Llc |
Fenilaminopirimidinamid autophágia inhibitorok és azok felhasználási eljárásai
|
|
ES3072710T3
(en)
|
2019-06-17 |
2026-07-03 |
Deciphera Pharmaceuticals Llc |
Aminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
HRP20260411T1
(hr)
|
2019-08-12 |
2026-05-08 |
Deciphera Pharmaceuticals, Llc |
Ripretinib za liječenje gastrointestinalnih stromalnih tumora
|
|
US12691108B2
(en)
|
2019-08-12 |
2026-07-28 |
Deciphera Pharmaceuticals, Llc |
Methods for treating vascular malformations
|
|
AU2020371727B2
(en)
|
2019-10-24 |
2026-01-22 |
Pierre Fabre Medicament |
Inhibitors of RAF kinases
|
|
FI4084779T3
(fi)
|
2019-12-30 |
2024-12-16 |
Deciphera Pharmaceuticals Llc |
1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
|
|
CN116034106B
(zh)
|
2020-06-02 |
2025-11-04 |
勃林格殷格翰国际有限公司 |
用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
|
|
WO2022060996A1
(en)
|
2020-09-18 |
2022-03-24 |
Kinnate Biopharma Inc. |
Inhibitors of raf kinases
|
|
US11377431B2
(en)
|
2020-10-12 |
2022-07-05 |
Kinnate Biopharma Inc. |
Inhibitors of RAF kinases
|
|
JP7805363B2
(ja)
|
2020-11-02 |
2026-01-23 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ＥＧＦＲ阻害薬としての置換１Ｈ－ピラゾロ［４，３－ｃ］及び誘導体
|
|
PE20231311A1
(es)
|
2020-11-18 |
2023-08-24 |
Deciphera Pharmaceuticals Llc |
Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos
|
|
AU2021409816A1
(en)
|
2020-12-22 |
2023-07-06 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
|
JP7825636B2
(ja)
|
2021-04-23 |
2026-03-06 |
ピエール ファーブル メディカモン |
（ｓ）－ｎ－（３－（２－（（（ｒ）－１－ヒドロキシプロパン－２－イル）アミノ）－６－モルホリノピリジン－４－イル）－４－メチルフェニル）－３－（２，２，２－トリフルオロエチル）ピロリジン－１－カルボキサミドおよびその塩の固体状態での形態
|
|
TW202308645A
(zh)
|
2021-04-23 |
2023-03-01 |
美商奇奈特生物製藥公司 |
使用raf抑制劑之癌症治療
|
|
US12065427B2
(en)
|
2021-04-29 |
2024-08-20 |
Boehringer Ingelheim International Gmbh |
Heterocyclic compounds capable of activating STING
|
|
TW202340208A
(zh)
|
2021-12-01 |
2023-10-16 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
|
|
TW202340209A
(zh)
|
2021-12-01 |
2023-10-16 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
|
|
EP4441051A1
(en)
|
2021-12-01 |
2024-10-09 |
Boehringer Ingelheim International GmbH |
Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
|
|
CR20240233A
(es)
|
2021-12-01 |
2024-07-17 |
Univ Vanderbilt |
Tiofenos 2-amino-3-ciano anulados y derivados para el tratamiento del cáncer
|
|
TW202337432A
(zh)
|
2021-12-01 |
2023-10-01 |
德商百靈佳殷格翰國際股份有限公司 |
用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
|
|
EP4441050A1
(en)
|
2021-12-01 |
2024-10-09 |
Boehringer Ingelheim International GmbH |
Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
MX2024006627A
(es)
|
2021-12-03 |
2024-08-22 |
Deciphera Pharmaceuticals Llc |
Inhibidores de gcn2 y perk quinasa y metodos de uso de los mismos.
|
|
AU2022405115A1
(en)
|
2021-12-09 |
2024-07-11 |
Deciphera Pharmaceuticals, Llc |
Raf kinase inhibitors and methods of use thereof
|
|
US12319655B2
(en)
|
2021-12-09 |
2025-06-03 |
Deciphera Pharmaceuticals, Llc |
RAF kinase inhibitors and methods of use thereof
|
|
EP4452975A1
(en)
|
2021-12-23 |
2024-10-30 |
Boehringer Ingelheim International GmbH |
8-aza quinazolines as brain-penetrant sos1-inhibitors
|
|
WO2023173017A1
(en)
*
|
2022-03-09 |
2023-09-14 |
Blossomhill Therapeutics, Inc. |
Kras inhibitors for treating disease
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|
|
AU2023370123A1
(en)
|
2022-10-26 |
2025-04-17 |
Boehringer Ingelheim International Gmbh |
Heterocyclic compounds capable of activating sting
|
|
US20240174642A1
(en)
|
2022-10-26 |
2024-05-30 |
Boehringer Ingelheim International Gmbh |
Heterocyclic compounds capable of activating sting
|
|
WO2024088991A1
(en)
|
2022-10-26 |
2024-05-02 |
Boehringer Ingelheim International Gmbh |
Heterocyclic compounds capable of activating sting
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
US20250019385A1
(en)
|
2023-05-30 |
2025-01-16 |
Boehringer Ingelheim International Gmbh |
Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
GB2633813A
(en)
|
2023-09-21 |
2025-03-26 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025083426A1
(en)
|
2023-10-20 |
2025-04-24 |
Sevenless Therapeutics Limited |
New treatments for pain
|
|
IL328681A
(en)
|
2023-12-08 |
2026-07-01 |
Deciphera Pharmaceuticals Llc |
Preparations containing vimseltinib
|
|
WO2025122942A1
(en)
|
2023-12-08 |
2025-06-12 |
Deciphera Pharmaceuticals, Llc |
Solid state forms of a kinase inhibitor
|
|
AU2024404879A1
(en)
|
2023-12-22 |
2026-06-25 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
|
WO2025146548A1
(en)
|
2024-01-04 |
2025-07-10 |
Sevenless Therapeutics Limited |
Sos1 inhibitors useful to treat pain and cancer
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202602876A
(zh)
|
2024-04-03 |
2026-01-16 |
德商百靈佳殷格翰國際股份有限公司 |
作為ｓｏｓ１抑制劑的新穎雙環芐基醯胺吡啶衍生物
|
|
TW202608862A
(zh)
|
2024-05-01 |
2026-03-01 |
美商迪賽孚爾製藥有限公司 |
製備ｃｓｆ－１ｒ抑制劑之方法及其使用方法
|
|
WO2025231106A1
(en)
|
2024-05-01 |
2025-11-06 |
Deciphera Pharmaceuticals, Llc |
Csf-1r inhibitors and methods of use thereof
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026114918A1
(en)
|
2024-11-27 |
2026-06-04 |
Boehringer Ingelheim International Gmbh |
Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras inhibitors for the treatment of cancer
|
|
US20260146050A1
(en)
|
2024-11-27 |
2026-05-28 |
Boehringer Ingelheim International Gmbh |
Kras degrading compounds comprising spirocyclic annulated 2 amino-3-cyano thiophenes
|
|
US20260146049A1
(en)
|
2024-11-27 |
2026-05-28 |
Boehringer Ingelheim International Gmbh |
Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
|
|
WO2026114957A1
(en)
|
2024-11-27 |
2026-06-04 |
Boehringer Ingelheim International Gmbh |
Spirocyclic annulated 2-amino-3-cyano thiophene derivatives as kras degraders for the treatment of cancer
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|